Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | IDO1 | P14902 | 2/20 | 0.44 |
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7157865 | 0.89 | CYP17A1 (0.45) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL3439957 | 0.89 | CA12 (0.45) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL7366510 | 0.87 | CA12 (0.44) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL6942064 | 0.87 | CA12 (0.44) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL6814479 | 0.87 | CA12 (0.44) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL4697286 | 0.87 | AURKB (0.53) | IDO1HPGDKMT2AMEN1CYP3A4 | |
| SCHEMBL509795 | 0.84 | CA12 (0.52) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL6681859 | 0.84 | KMT2A (0.43) | CA12CA1CA9POLBCYP17A1 | |
| SCHEMBL16303890 | 0.83 | EPHX1 (0.58) | CA12CA1CA9POLBHPGD | |
| SCHEMBL20157848 | 0.83 | CA12 (0.45) | CA12CA1CA9CYP17A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309554-B2 | Hypoxia activated drugs of nitrogen mustard alkylators | THRESHOLD PHARMACEUTICALS (US) | 2012-11-13 | — | — | US | disclosed |
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | THRESHOLD PHARMACEUTICALS, INC. | 2011-08-04 | — | — | US | disclosed |
| WO-2009140553-A2 | HYPOXIA ACTIVATED DRUGS OF NITROGEN MUSTARD ALKYLATORS | THRESHOLD PHARMACEUTICALS, INC. (US) | 2009-11-19 | — | — | WO | disclosed |
| EP-0798292-B1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | CHUGAI SEIYAKUKABUSHIKI KAISHA (JP) | 2004-11-03 | — | — | EP | disclosed |
| US-6534546-B1 | Guanidine- or isothioureido-N-derived anilines; brain, nervous system, and neurodegenerative disorders | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-03-18 | — | — | US | disclosed |
| EP-0798292-A1 | ANILINE DERIVATIVES HAVING NITROGEN MONOXIDE SYNTHASE INHIBITORY ACTIVITY | Chugai Seiyaku Kabushiki Kaisha (JP) | 1997-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190310-A1 | Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators | HIF1AN, HIF1A, HYOU1 | CA12 474/4885CA1 377/4885CA9 99/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.